The Goose Data interview

Publisher’s Note: Join us September 11-14 in Philadelphia for Digital Pharma East! We’re excited to announce our opening keynote, none other than Dustin Garis, world-renowned brand innovator, customer experience pioneer and Chief Troublemaker. Register today for the ultimate marketing event in the life sciences industry.

Today's Big News

Aug 2, 2023

A ‘painful reset' for biotech investing brings smaller checks but some green shoots: SVB


CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial


It's Goose Data's (online) world, and biotechs are just sitting ducks


Surface warns bankruptcy possible if shareholders reject Coherus merger


City of Hope's cancer-killing pill works like a snowstorm shutting down an airport


Scleroderma clinical trial initiative snags Sanofi as first partner to accelerate research

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

A 'painful reset' for biotech investing brings smaller checks but some green shoots: SVB

Early-stage investments in biopharma are up this year, but valuations have come way down. investors are looking for proven leadership teams and an exit strategy that does not involve waiting for the IPO window to magically open up, according to a new H1 analysis by Silicon Valley Bank.
11-14
Sep
Philadelphia, PA
 

Top Stories

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical trial has persuaded investors to dig out their checkbooks and pump $105 million into the business.

It's Goose Data's (online) world, and biotechs are just sitting ducks

We take protecting anonymous sources around here seriously. So when we do use one, you know the subject is important. Fierce Biotech tracked down the Twitter/X biotech meme over lord/lady Goose Data.

Surface warns bankruptcy possible if shareholders reject Coherus merger

Surface Oncology has shown investors the ghost of biotech yet to come. Needing shareholder support for its planned merger with Coherus BioSciences, the biotech has told investors that outlays triggered by the deal have shrunk its cash runway and will leave it needing funding fast if the deal collapses.

City of Hope's cancer-killing pill works like a snowstorm shutting down an airport

Researchers from City of Hope have pinned down the mechanism behind an oral chemotherapy that is already being tested in humans, adding weight to the preclinical package of data underpinning the drug's potential in a range of solid tumors. 

Scleroderma clinical trial initiative snags Sanofi as first partner to accelerate research

Sanofi will be the inaugural partner for the Scleroderma Research Foundation’s new clinical trial initiative to advance treatments for the rare autoimmune disorder of the skin and organs.

Abbott pulls Trifecta heart valves from market after early deterioration risks

In February, Abbott and the FDA notified clinicians that studies pointed toward higher rates of aortic valve implant failures in the first five years.

Merck still scouting for M&A deals, even after $10.8B takeover of Prometheus

Merck’s $10.8 billion acquisition of Prometheus Biosciences earlier this year gave the New Jersey company increased diversity in its portfolio, much needed considering its overwhelming dependence on cancer juggernaut Keytruda. But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said.

'The danger is great and growing': Healthcare experts call on industry to reduce the risks of nuclear war

The world hasn't been this close to nuclear war since the Cold War, say experts. Editors of prestigious medical journals sound a call to disarm.

As COVID revenues disappoint, once-high-flying Pfizer looks at possible cost cuts

Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period last year.

CVS Health cuts 5,000 corporate jobs amid push to 'reprioritize' healthcare investments

Those affected will reportedly receive severance pay, benefits and help with landing a new job elsewhere. CVS Health does not expect customer-facing roles in stores, pharmacies and clinics to be affected in the layoff plan.
 
Fierce podcasts

Don't miss an episode

'Podnosis': A critical look at value-based care

This week on "Podnosis," we take a critical look at value-based care. Also under discussion is the top nonprofit health systems of 2022.
 

Resources

Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.
Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives.
Research

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
Whitepaper

Improving the Patient Experience Through Research-Driven Design

Learn more about the current challenges and issues that eClinical technology providers are facing.

 

Industry Events

 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events